Innate Pharma SA IPH-FR:Euronext Paris

*Data is delayed | EUR
Last | 10/22/21 CEST
4.85quote price arrow down-0.10 (-2.06%)
Volume
202,465
52 week range
2.57 - 8.30
Loading...
  • Open4.96
  • Day High5.05
  • Day Low4.84
  • Prev Close4.95
  • 52 Week High8.30
  • 52 Week High Date09/17/21
  • 52 Week Low2.57
  • 52 Week Low Date07/19/21

Key Stats

  • Market Cap445.91M
  • Shares Out79.01M
  • 10 Day Average Volume348,684.73
  • Dividend-
  • Dividend Yield-
  • Beta0.52
  • YTD % Change40.03

KEY STATS

  • Open4.96
  • Day High5.05
  • Day Low4.84
  • Prev Close4.95
  • 52 Week High8.30
  • 52 Week High Date09/17/21
  • 52 Week Low2.57
  • 52 Week Low Date07/19/21
  • Market Cap445.91M
  • Shares Out79.01M
  • 10 Day Average Volume348,684.73
  • Dividend-
  • Dividend Yield-
  • Beta0.52
  • YTD % Change40.03

RATIOS/PROFITABILITY

  • EPS (TTM)-0.98
  • P/E (TTM)-4.95
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Innate Pharma SA

There is no recent news for this security.

Content From Our Affiliates

Profile

MORE
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic...
Laure-Helene Mercier
Chief Financial Officer
Yannis Morel Ph.D.
Executive Vice President
Joyson Karakunnel
Executive Vice President
Jennifer Butler
Executive Vice President
Odile Belzunce
Vice President
Address
117 avenue de Luminy, Bp 30191
Marseille
13009
France